

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-20 (Cancelled)

21. (previously presented) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence having 98% sequence homology or greater to SEQ ID NO: 4.
22. (previously presented) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises SEQ ID NO: 4.
23. (previously presented) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence having 98% sequence homology or greater to SEQ ID NO: 2.
24. (previously presented) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence having 98% sequence homology or greater to SEQ ID NO: 3.
25. (cancelled)

26. (previously presented) The antibody according to claim 21 which is a monoclonal antibody or fragment thereof.

27. (previously presented) The antibody according to claim 22 which is a monoclonal antibody or fragment thereof.

28. (previously presented) The antibody according to claim 23 which is a monoclonal antibody or fragment thereof.

29. (previously presented) The antibody according to claim 24 which is a monoclonal antibody or fragment thereof.

30. (previously presented) A recombinant cell expressing the antibody according to any one of claims 21-24 and 26-29.

31. (cancelled)

32. (cancelled)

33. (currently amended) A method for treating an angiogenesis related disease or disorder comprising administering an effective amount of an antibody of any one of claims ~~21-29 or 31-32~~ 21-24 or 26-29 to a patient in need thereof.